Pharma IQ Glossary: Amorphous Solids
Amorphous Solids are solids that have a disordered atomic structure. In contrast, solids that exhibit long-range order in the atomic positions are called crystallines or morphous. Most classes of solid materials can be found or prepared in an amorphous form. For instance, common window glass is an amorphous solid, many polymers (such as polystyrene) are amorphous, and even junk foods such as cotton candy are amorphous solids.
Understand Amorphous Materials in 8 Minutes
September 02 by Niamh MadiganOne of the main challenges when working with Amorphous materials is being able to predict and characterise properties which are common to crystalline products. Yaroslav Khimyak, Professor in NMR at th...
Survey: Improving Solubility 2012
April 27 by Pharma IQ SurveysIn preparation for the 8th Annual Improving Solubility Summit, taking place in June, Pharma IQ would like to invite you to take part in a short survey. The survey consists of no more than 8 questions...
Ensuring Stability the Biggest Amorphous Challenge for 88.2% of Developers
July 27 by Pharma IQThe use of amorphous pharmaceutical materials is widely considered an effective way of improving favourable drug properties and the latest findings from Pharma IQ suggest that many developers consider...
The Rise of Academic/Industry Collaboration in Amorphous Material Studies
May 30 by Helen WinsorMarc Descamps, Professor in Solid State Physics at Université Lille and Lead of the European ID Network for Improved Drug Efficacy and Availability, joins Helen Winsor from Pharma IQ, to discuss the u...
Spray-Dried Dispersion Technology: Solving Drug Solubility Challenges
March 09 by Amber ScorahAmorphous spray dried dispersions (SDDs) have emerged as a broadly applicable technology for the delivery of poorly soluble drug molecules. Methods for formulating and predicting the physical stabilit...
Investing in Techniques for Developing Amorphous Materials
February 13 by Pharma IQThe use of amorphous materials presents many opportunities for the pharmaceutical industry in terms of increased solubility and bioavailability, particularly as a growing number of insoluble active ph...
Implementing Thermal Processing Technologies for the Production of Amorphous Solid Dispersions
September 05 by Helen WinsorAmorphous pharmaceutical materials are now being recognised as an attractive alternative route for solid state development. Dr. Dave Miller, Senior Principal Scientist at Hoffmann-La Roche, speaks to...
Pfizer, Sanofi-Aventis, Novartis, GlaxoSmithKline, Abbott Laboratories and Merck to Speak at the 9th Polymorphism & Crystallization Scientific Forum
August 24 by Pharma IQ NewsThere has been increased focus on using crystals and the ever-changing, sometimes disappearing properties of polymorphs as significant scientific and business opportunities. IQPC’s Polymor...
The Challenges of Amorphous Solid Dispersion Production: A Hoffman La Roche Perspective
July 11 by Pharma IQDr. Dave Miller, Senior Principal Scientist at Hoffmann La Roche, shares his views on how to optimise amorphous form selection, techniques to enhance amorphous drug performance and the best strategies...
Be Prepared for Scale Up of Co-crystal Production
July 06 by Vaibhav SihorkarDr. Vaibhav Sihorkar, Head of Pharmaceutical Development at Aurigene Discovery Technologies in India, gave Pharma IQ his insights on existing challenges to co-crystal commercialisation. Wha...
Making Drug Formation Crystal Clear
June 17 by Pharma IQThe perfect ingredients and compounds help to make many drugs effective, but the very best medicines developed by the pharmaceutical sector are also formulated to react in the most suitable way once...
Choosing the Best Techniques for Developing Amorphous Materials
June 13 by Pharma IQThe amorphous state is inherently instable. How do we keep amorphous forms from crystallising for as long as possible? Dr. Joseph Lubach from Genentech, joined Pharma IQ to discuss the challenges of p...
